NURIX THERAPEUTICS, INC. Deferred Offering Costs
NURIX THERAPEUTICS, INC. (NRIX) had Deferred Offering Costs of $100.00 thousand as of 2025-11-30, per its 10-K filed 2026-01-28.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-01-28
- 2025-11-30: Deferred Offering Costs $100.00K.
- 2024-11-30: Deferred Offering Costs $100.00K.
- 2023-11-30: Deferred Offering Costs $500.00K.
- 2022-11-30: Deferred Offering Costs $500.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2025-11-30 | $100.00K 10-K · filed 2026-01-28 |
| 2024-11-30 | $100.00K 10-K · filed 2026-01-28 |
| 2023-11-30 | $500.00K 10-K · filed 2025-01-28 |
| 2022-11-30 | $500.00K 10-K · filed 2024-02-15 |
| 2021-11-30 | $500.00K 10-K · filed 2023-02-09 |
| 2020-11-30 | $0.00 10-K · filed 2022-01-28 |
| 2020-08-31 | $0.00 10-Q · filed 2020-10-14 |
| 2019-11-30 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |